BeiGene Total Non-Cash Items 2014-2024 | ONC
BeiGene annual/quarterly total non-cash items history and growth rate from 2014 to 2024. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- BeiGene total non-cash items for the quarter ending September 30, 2024 were $0.415B, a 1318.13% decline year-over-year.
- BeiGene total non-cash items for the twelve months ending September 30, 2024 were $0.844B, a 36.02% increase year-over-year.
- BeiGene annual total non-cash items for 2023 were $0.095B, a 74.71% decline from 2022.
- BeiGene annual total non-cash items for 2022 were $0.375B, a 35.1% increase from 2021.
- BeiGene annual total non-cash items for 2021 were $0.277B, a 66.65% increase from 2020.
BeiGene Annual Total Non-Cash Items
(Millions of US $) |
| 2023 |
$95 |
| 2022 |
$375 |
| 2021 |
$277 |
| 2020 |
$166 |
| 2019 |
$211 |
| 2018 |
$144 |
| 2017 |
$49 |
| 2016 |
$15 |
| 2015 |
$15 |
| 2014 |
$11 |
| 2013 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
